Shenzhen YHLO Biotech's high P/E ratio may not be justified ...
Shenzhen YHLO Biotech's high P/E ratio may not be justified by its growth outlook. Investors may face disappointment if the P/E falls to levels more in line with the growth outlook. The current high share price is seen as unreasonable given the predicted future earnings.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000015663fb38fbf06.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment